Table 1.
Demographic and treatment characteristics of the survivor and sibling cohorts.
| Survivors (n=1426) | Siblings (n=384) | |||
|---|---|---|---|---|
| Mean (SD) | Range | Mean (SD) | Range | |
| Age at Diagnosis | 11.9 (5.6) | 0–21 | --- | --- |
| Time Since Diagnosis | 24.0 (4.7) | 16.2– 34.3 | --- | --- |
| Current Age | 35.9 (7.5) | 19.2–53.4 | 33.7 (8.4) | 17.8–58.4 |
| Frequency | Percent | Frequency | Percent | |
| Sex | ||||
| Male | 684 | 48.0 | 181 | 47.9 |
| Female | 742 | 52.0 | 199 | 52.1 |
| Income | ||||
| <20,000 | 135 | 9.5 | 24 | 6.3 |
| 20,000–39,999 | 250 | 17.5 | 58 | 15.1 |
| ≥40,000 | 919 | 64.5 | 271 | 71.9 |
| Cancer Diagnosis | ||||
| Leukemia | 200 | 14.0 | --- | --- |
| CNS tumor | 214 | 15.0 | --- | --- |
| Hodgkin Lymphoma* | 768 | 53.9 | --- | --- |
| Other Cancer | 244 | 17.1 | --- | --- |
| Chemotherapy Treatment | ||||
| Alkylators | 721 | 50.6 | --- | --- |
| Anthracycline | 407 | 28.5 | --- | --- |
| Antimetabolite (IV) | 265 | 18.6 | --- | --- |
| Antimetabolite (IT) | 795 | 55.8 | --- | --- |
| Corticosteroids | 538 | 38 | --- | --- |
| Epipodophyllotoxin | 45 | 3.2 | --- | --- |
| Cranial Radiation Treatment (CRT) | ||||
| NO CRT | 309 | 21.7 | --- | --- |
| CRT <20Gy | 779 | 54.6 | --- | --- |
| CRT ≥ 20Gy | 201 | 14.1 | --- | --- |
*
Survivors diagnosed with and treated for Hodgkin Lymphoma were over-represented in the current sample, given the higher rates of reported fatigue and sleep problems.